MELBOURNE, Australia — Telix Pharmaceuticals Ltd. shares surged more than 7% Friday as the Australian radiopharmaceutical company received a key regulatory boost in the United States, highlighting its growing role in precision oncology diagnostics and therapeutics.

Telix Pharmaceuticals
Telix Pharmaceuticals

Telix (ASX: TLX) stock climbed A$1.00, or 7.33%, to A$14.64 by the close of trading on the Australian Securities Exchange at 4:16 p.m. GMT+10. The move extended gains that have seen the stock rise about 31% over the past month, fueled by robust commercial performance and pipeline advancements in the fast-expanding field of targeted radiopharmaceuticals.

The rally was triggered by Telix's announcement that the U.S. Food and Drug Administration accepted its resubmitted New Drug Application for TLX101-Px, known as Pixclara (18F-FET), an imaging agent designed to improve diagnosis and management of glioma, the most common form of primary brain cancer. The FDA set a Prescription Drug User Fee Act target action date of Sept. 11, 2026, for the potential approval.

Pixclara aims to address limitations of current imaging techniques by providing better visualization of brain tumors, potentially aiding more accurate treatment planning for patients facing this aggressive disease. Telix also filed a Marketing Authorization Application for the product, branded Pixlumi in Europe, advancing its global regulatory strategy for the asset.

"This acceptance marks another important milestone as we work to bring innovative radiopharmaceutical solutions to patients with high unmet needs," Telix executives noted in recent communications, emphasizing the company's dual focus on diagnostics and therapeutics.

Telix specializes in developing and commercializing targeted radiopharmaceuticals that combine radioactive isotopes with molecules designed to bind to specific cancer markers. Its portfolio includes approved imaging agents and late-stage therapeutic candidates for prostate, kidney, brain and other cancers.

The company's flagship products — Illuccix and Gozellix, both gallium-68 PSMA-PET imaging agents for prostate cancer — drove much of its recent growth. These tools help clinicians detect and stage prostate cancer more precisely than traditional methods, guiding decisions on surgery, radiation and systemic therapies.

In its Q1 2026 business update released earlier this week, Telix reported unaudited group revenue of US$230 million, up 11% from the previous quarter and 24% year-over-year. Precision Medicine revenue, which includes Illuccix and Gozellix sales, reached US$186 million, a 16% sequential increase, reflecting strong U.S. dose volume growth and international expansion.

The company reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, implying continued double-digit growth following 2025's robust performance. For the full year 2025, Telix posted revenue of approximately US$803.8 million, a 56% jump from the prior year, driven by higher Illuccix volumes and the successful U.S. launch of Gozellix after securing reimbursement.

Analysts have responded positively. Wedbush maintained an Outperform rating with a US$22 price target, while H.C. Wainwright reiterated a Buy rating at US$20. Consensus targets hover around US$21, suggesting significant upside from current levels on both ASX and Nasdaq listings. Some forecasts point to potential revenue approaching US$1.5 billion by 2028 if pipeline assets reach commercialization.

Beyond diagnostics, Telix is advancing a therapeutics pipeline that could transform its business model from primarily imaging-focused to a balanced diagnostics-and-therapy player. Its lead candidate, TLX591 (lutetium-177 rosopatamab tetraxetan), is in the ProstACT Global Phase 3 trial for PSMA-positive metastatic castration-resistant prostate cancer.

Part 1 of the study, a lead-in safety and dosimetry evaluation, recently met its objectives with no new safety signals observed, supporting progression to the randomized portion. The therapy uses a radio-antibody drug conjugate approach to deliver targeted radiation directly to cancer cells while sparing healthy tissue.

Additional candidates include TLX250 for kidney cancer and TLX101 for brain cancer therapeutics, part of a strategy to pair diagnostic imaging with companion therapies — often called "theranostics" — in a single integrated approach.

Telix has invested heavily in manufacturing and supply chain capabilities to support growth. It operates facilities in key markets and has pursued strategic acquisitions to secure isotope supply and expand production. Year-end 2025 cash stood at US$141.9 million after significant investments, with ongoing R&D guidance for 2026 set at US$200 million to US$240 million.

The radiopharmaceutical sector has attracted intense investor interest amid breakthroughs in targeted cancer treatments. Major players and newcomers alike are racing to develop agents that improve outcomes while reducing side effects compared to traditional chemotherapy or broad radiation.

Telix's vertically integrated model — spanning development, manufacturing and commercialization — positions it to capture more value across the supply chain. The company has expanded internationally, with operations in the United States, Europe, Japan, Brazil and elsewhere, and continues seeking approvals in additional markets for Illuccix and Gozellix.

Recent corporate moves include board strengthening with new non-executive director appointments and routine securities filings, including issuance of shares upon conversion of unquoted securities and notifications regarding substantial holders.

Despite the momentum, challenges remain. Radiopharmaceutical production involves complex logistics due to short isotope half-lives, requiring sophisticated cold-chain and just-in-time manufacturing. Regulatory hurdles can delay launches, as seen with previous FDA requests for additional data on certain assets. Competition is intensifying from larger pharmaceutical companies and specialized biotech firms entering the space.

Gross margins have held steady around 53% in recent periods, though increased R&D and commercial infrastructure spending have pressured adjusted EBITDA, which came in at US$39.5 million for 2025. Management has signaled a focus on scaling efficiently while prioritizing late-stage pipeline acceleration.

Market watchers note that success in the upcoming PDUFA date for Pixclara, combined with ProstACT data readouts, could serve as major catalysts. Positive outcomes might accelerate adoption of Telix's platform and support premium valuations typical of high-growth biotech names with approved products and robust pipelines.

Founded in Melbourne, Telix has grown rapidly since its early days, transitioning from a development-stage company to one with commercial revenues and global reach. It maintains dual listings on the ASX and Nasdaq, broadening its investor base.

Broader industry tailwinds include rising cancer incidence, improved awareness of PSMA-PET imaging benefits, and policy support for innovative oncology therapies. Governments and payers increasingly recognize the value of precise diagnostics in reducing unnecessary procedures and optimizing treatment.

Friday's trading volume on the ASX was elevated as investors digested the FDA news alongside the solid Q1 performance. Technical charts show the stock breaking out from recent consolidation, though it remains below all-time highs reached during earlier enthusiasm phases.

As Telix prepares for potential Pixclara approval later this year and further clinical data, attention will turn to execution on revenue guidance, margin trends and pipeline milestones. Analysts will scrutinize any commentary on manufacturing scale-up and international launches during future updates.

For now, the combination of commercial traction in prostate cancer imaging and progress toward brain cancer diagnostics has reignited optimism around Telix's theranostics platform. With the global radiopharmaceutical market projected to expand significantly, the company appears well-placed to benefit from the shift toward personalized, targeted cancer care.